TY - JOUR T1 - Should aPS/PT Be Incorporated into the Routine Serological Tests in the Diagnosis of Antiphospholipid Syndrome? JF - The Journal of Rheumatology JO - J Rheumatol SP - 114 LP - 116 DO - 10.3899/jrheum.171402 VL - 46 IS - 1 AU - SHULAN ZHANG AU - FENGCHUN ZHANG AU - YONGZHE LI Y1 - 2019/01/01 UR - http://www.jrheum.org/content/46/1/114.abstract N2 - We read with great interest the article by Zohoury, et al1 on how to close the serological gap in the diagnosis of antiphospholipid syndrome (APS) by using non-criteria antiphospholipid antibodies (aPL). In their well-designed study, the authors found that using 4 of 11 non-criteria tests [antiphosphatidylserine/prothrombin complex (aPS/PT), antiphosphatidylserine (aPS), antiphosphatidylethanolamine antibodies, and anticardiolipin (aCL)/vimentin antibodies], an accumulative 30.9% of seronegative APS (SN-APS) patients were detected, and there was a further 5.9% increase when using the other 7 non-criteria tests. On the basis of their findings, the authors concluded that patients displaying clinical features of APS but negative for conventional criteria markers should undergo additional testing for non-criteria biomarkers.Among those non-criteria biomarkers, aPS/PT has exhibited the most promising potential owing to the availability of the well-characterized and standardized commercial ELISA kits2. In this letter, we hope to contribute to this discussion by calling attention to an additional report that we recently published on the clinical relevance of aPS/PT in Chinese patients with APS3.In our study, sera from 441 subjects were analyzed, including … Address correspondence to Dr. Y. Li, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Eastern District, Beijing 100730, China. E-mail: LiYZ{at}pumch.cn or yongzhelipumch{at}126.com ER -